By Josh Beckerman
Catalyst Pharmaceuticals and its licensor SERB entered into a settlement agreement with Teva Pharmaceuticals resolving patent litigation brought by Catalyst and SERB in response to Teva's plans for a generic version for Firdapse 10 mg tablets.
Catalyst said Teva won't market its potential generic version of Firdapse in the U.S. any earlier than Feb. 25, 2035, unless "certain limited circumstances customarily included in these types of agreements occur."
Firdapse is a treatment for Lambert-Eaton myasthenic syndrome.
Catalyst shares were down 1.8% at $19.18 prior to a trading halt.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 08, 2025 12:42 ET (17:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。